GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-si
January 11, 2021
· 3 min read